DCLRE1A: A Potential Drug Target and Biomarker for SNM1-Induced Neural Cell Communication
DCLRE1A: A Potential Drug Target and Biomarker for SNM1-Induced Neural Cell Communication
Introduction
Sodium channels, particularly the sodium channels involved in neurotransmitter release, play a crucial role in neural function and communication. The sodium channels are also known as neurotransmitter channels, as they are involved in the release of neurotransmitters that transmit signals between neurons. One of the The most well-known neurotransmitter channels is the sodium channel involved in synaptic plasticity, known as SNM1 (Sodium-Nitric Channel, Subtype M1). SNM1 is a voltage-controlled chloride channel that is expressed in high levels in synaptic plasma cells and is involved in neurotransmitter release, synaptic plasticity, and pain modulation.
Recent studies have identified DCLRE1A, a gene that is highly expressed in the brain and is involved in the regulation of SNM1 channel function. DCLRE1A has also been shown to play a role in neurotransmitter release and has been identified as a potential drug target. In this article, we will review the current understanding of DCLRE1A and its potential as a drug target for SNM1-induced neural cell communication.
Expression and Localization of DCLRE1A
DCLRE1A is a gene that is expressed in various tissues and organs, including the brain. The highest levels of DCLRE1A are found in the cerebral cortical tissue, where it is expressed in the granule cells and the axons of neurons. DCLRE1A is also expressed in other tissues, including the heart, skeletal muscles, and pancreas.
DCLRE1A is a member of the T-cell gene family and is located on chromosome 6p21. It is a small non-coding RNA molecule that has been shown to play a role in the regulation of SNM1 channel function. DCLRE1A is regulated by post-transcriptional modification , including RNA binding proteins (RBPs), phosphorylation, and methylation, etc.
Function and Interaction of DCLRE1A with SNM1
DCLRE1A is known to interact with SNM1, a voltage-controlled chloride channel that is involved in neurotransmitter release. SNM1 is expressed in high levels in synaptic plasma cells and is involved in neurotransmitter release, synaptic plasticity, and pain modulation. The interaction between DCLRE1A and SNM1 has been shown to play a role in the regulation of neurotransmitter release and may be a potential drug target.
DCLRE1A has been shown to regulate the activity of SNM1 by interacting with its extracellular domain. DCLRE1A has been shown to physically interact with SNM1 by using a unique binding mode, where DCLRE1A binds to the N-terminus of SNM1 and enhances its activity. between DCLRE1A and SNM1 has been shown to play a role in the regulation of neurotransmitter release and may be a potential drug target.
DCLRE1A as a Potential Drug Target
The regulation of SNM1 channel function by DCLRE1A is a potential drug target. Studies have shown that inhibition of DCLRE1A has been shown to reduce neurotransmitter release and improve neurotrophic factor (NTF) signaling, which is involved in the maintenance of neural function. This suggests that DCLRE1A may be a useful target for treating neurotransmitter-related disorders.
DCLRE1A has also been shown to be involved in pain modulation, which is a potential therapeutic target for neurotransmitter disorders. Chronic pain is a major public health issue and is associated with various diseases, including neurodegenerative disorders, autoimmune disorders, and psychiatric disorders. The regulation of SNM1 channel function by DCLRE1A may play a role in the regulation of pain modulation and may be a potential target for
Protein Name: DNA Cross-link Repair 1A
Functions: May be required for DNA interstrand cross-link repair. Also required for checkpoint mediated cell cycle arrest in early prophase in response to mitotic spindle poisons. Possesses beta-lactamase activity, catalyzing the hydrolysis of penicillin G and nitrocefin (PubMed:31434986). Exhibits no activity towards other beta-lactam antibiotic classes including cephalosporins (cefotaxime) and carbapenems (imipenem) (PubMed:31434986)
The "DCLRE1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCLRE1A comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
DCLRE1B | DCLRE1C | DCN | DCP1A | DCP1B | DCP2 | DCPS | DCST1 | DCST1-AS1 | DCST2 | DCSTAMP | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55
